CG Invites Co., Ltd. (KOSDAQ: 083790)

Market Cap	178.01B
Revenue (ttm)	5.57B
Net Income (ttm)	-60.53B
Shares Out	76.89M
EPS (ttm)	-790.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	49,606
Average Volume	80,373
Open	2,280.00
Previous Close	2,275.00
Day's Range	2,245.00 - 2,325.00
52-Week Range	2,015.00 - 4,385.00
Beta	-0.12
RSI	35.21
Earnings Date	Mar 19, 2025

About CG Invites

CG Invites Co., Ltd., a biopharma company, engages in the discovery and development of structural chemoproteiomics-based drugs in Korea. It offers Acelex (polmacoxib), an anti-inflammatory and pain relief drug, as well as CG-650, an anti-inflammatory drug, currently under phase 1 stage for the treatment of osteoarthritis; CG-651, an anti-inflammatory drug, currently under phase 1 stage for the treatment of neuropathic pain; and CG-652, an anti-inflammatory drug, currently under phase 1 stage for the treatment of rheumatoid arthritis. The compan...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 75
• Stock Exchange: KOSDAQ
• Ticker Symbol: 083790

Financial Performance

In 2023, CG Invites's revenue was 4.88 billion, an increase of 12.90% compared to the previous year's 4.32 billion. Losses were -48.92 billion, 105.0% more than in 2022.